Next generation of small molecules in inflammatory bowel disease

Gut

Volumn 66, Issue 2, 2017, Pages 199-209

  Olivera, Pablo ^a,b   Danese, Silvio ^c   Peyrin Biroulet, Laurent ^b  

^a CEMIC   (Argentina)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c HUMANITAS UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISELIMOD; AMYLASE; APREMILAST; C REACTIVE PROTEIN; ETRASIMOD; FILGOTINIB; FINGOLIMOD; GED 0507 34; GLPG 0974; GSK 1399686; GSK 2982772; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JANUS KINASE INHIBITOR; LAQUINIMOD; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LT 02; LYC 30937 EC; MONGERSEN; NATALIZUMAB; OZANIMOD; PEFICITINIB; ROSIGLITAZONE; TAK 828; TD 1473; TOFACITINIB; TOP 1288; UNCLASSIFIED DRUG; UPADACITINIB; VB 201; VIDOFLUDIMUS; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; INDAN DERIVATIVE; OXADIAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ABSCESS; AMYLASE BLOOD LEVEL; ANTIGENICITY; ATRIOVENTRICULAR BLOCK; BACKACHE; BRADYCARDIA; BREAST CANCER; CANDIDIASIS; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CRYPTOCOCCAL MENINGITIS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GASTROENTERITIS; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INFLUENZA; INTESTINE PERFORATION; LUNG DISEASE; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; PATIENT SATISFACTION; PERIANAL ABSCESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POST HOC ANALYSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; VOMITING; ANTAGONISTS AND INHIBITORS; INFLAMMATORY BOWEL DISEASE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INDANS; INFLAMMATORY BOWEL DISEASES; OXADIAZOLES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84998978774     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312912     Document Type: Review

References (120)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
2. Umanskiy K, Fichera A. Health related quality of life in inflammatory bowel disease: the impact of surgical therapy. World J Gastroenterol 2010;16:5024-34.
3. Burisch J, Jess T, Martinato M, , et al. The burden of inflammatory bowel disease in Europe. J Crohn's Colitis 2013;7:322-37.
4. Faubion WA, Loftus EV, Harmsen WS, , et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
5. Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
6. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, , et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29.
7. Hanauer SB, Feagan BG, Lichtenstein GR, , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
8. Rutgeerts P, Sandborn WJ, Feagan BG, , et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2005;353:2462-76.
9. Colombel J-F, Sandborn WJ, Rutgeerts P, , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
10. Sandborn WJ, van Assche G, Reinisch W, , et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e3.
11. Sandborn WJ, Feagan BG, Stoinov S, , et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
12. Schreiber S, Khaliq-Kareemi M, Lawrance IC, , et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
13. Sandborn WJ, Feagan BG, Marano C, , et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95.
14. Feagan BG, Rutgeerts P, Sands BE, , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
15. Sandborn WJ, Feagan BG, Rutgeerts P, , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
16. Wils P, Bouhnik Y, Michetti P, , et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 2016;14:242-250.e2.
17. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369:754-62.
18. Allez M, Karmiris K, Louis E, , et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J Crohn's Colitis 2010;4:355-66.
19. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for Adalimumab dose intensification in crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84.
20. Roda G, Jharap B, Neeraj N, , et al. Loss of response to anti-TNFs: definition, epidemiology, management. Clin Transl Gastroenterol 2016;7: e135.
21. Ben-Horin S, Chowers Y. Review article: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-95.
22. Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther 2016;16:1277-90.
23. Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623: S17-25.
24. Baert F, Noman M, Vermeire S, , et al. Influence of Immunogenicity on the long-term efficacy of infliximab in Crohn's Disease. N Engl J Med 2003;348:601-8.
25. Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-monotherapy versus combination therapy with an Immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56.
26. Torres J, Boyapati RK, Kennedy NA, , et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015;149:1716-30.
27. van der Valk ME, Mangen M-JJ, Leenders M, , et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFtherapy: results from the COIN study. Gut 2014;63:72-9.
28. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care 2016;22:s51-60.
29. Buisson A, Seigne AL, D'Huart MC, , et al. The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2464-7.
30. Hanke T, Merk D, Steinhilber D, , et al. Small molecules with anti-inflammatory properties in clinical development. Pharmacol Ther 2016;157:163-87.
31. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90.
32. Samanen J. Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. In: Ganellin CR, Jefferis R, Roberts S, Eds. Introduction to biological and small molecule drug research and development: theory and case studies. Oxford: Elsevier Ltd, 2013:161-203.
33. Veber DF, Johnson SR, Cheng HY, , et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45: 2615-23.
34. Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small moleculesBMC Med 2014;12:43.
35. Remicade® [Package insert]. Horsham, PA: Janssen Biotech, Inc., 2013.
36. Littlechild JA. Protein structure and function. In: Introduction to biological and small molecule drug research and development. Oxford: Elsevier Ltd, 2013:57-79.
37. Klunk LJ. Considerations for a Scientifically Rational Approach to Biologics-Small Molecule DDI Studies. New England Drug Metabolism Discussion Group Summer Symposium. 2010.
38. Wright S, Yelland M, Heathcote K, , et al. Fear of needles-nature and prevalence in general practice. Aust Fam Physician 2009;38:172-6.
39. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61:1922-30.
40. Cramer JA, Roy A, Burrell A, , et al. Medication compliance and persistence: terminology and definitions. Value Heal 2008;11:44-7.
41. Depont F, Berenbaum F, Filippi J, , et al. Interventions to improve adherence in patients with immune-mediated inflammatory disorders: a systematic review. PLoS ONE 2015;10:e0145076.
42. Vangeli E, Bakhshi S, Baker A, , et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 2015;32:983-1028.
43. Lopez A, Billioud V, Peyrin-Biroulet C, , et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19:1528-33.
44. Harnett J, Curtis JR, Gerber R, , et al. Initial experience with tofacitinib in clinical practice: treatment patterns and costs of Tofacitinib administered as Monotherapy or in combination with conventional synthetic DMARDs in 2 US health care claims databases. Clin Ther 2016;38:1451-63.
45. Zink A, Listing J, Kary S, , et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
46. Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc 2004;1:24-9.
47. Carton JM, Strohl WR. Protein therapeutics (introduction to biopharmaceuticals). In: Introduction to biological and small molecule drug research and development: theory and case studies. Oxford: Elsevier Ltd, 2013:127-59.
48. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
49. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, cancer. N Engl J Med 2013;368:161-70.
50. Coskun M, Salem M, Pedersen J, , et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013;76:1-8.
51. Danese S, Grisham MB, Hodge J, , et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2015;310:G155-62.
52. Clark JD, Flanagan ME, Telliez JB. Discovery and Development of Janus Kinase ( JAK) Inhibitors for Inflammatory Diseases. J Med Chem 2014;57:5023-38.
53. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:513-26.
54. Fleischmann R, Kremer J, Cush J, , et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
55. Lee EB, Fleischmann R, Hall S, , et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
56. van Vollenhoven RF, Fleischmann R, Cohen S, , et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
57. Bachelez H, van de Kerkhof PCM, Strohal R, , et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015;386:552-61.
58. Papp KA, Menter MA, Abe M, , et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015;173:949-61.
59. Sandborn WJ, Ghosh S, Panes J, , et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
60. Sandborn W, Sands BE, D'Haens GR, , et al. 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials [Abstract]. Gastroenterology 2016;150:S157.
61. Sandborn WJ, Ghosh S, Panes J, , et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with crohn's disease. Clin Gastroenterol Hepatol 2014;12:1485-1493.e2.
62. Panés J, Sandborn W, Schreiber S, , et al. 855 Efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial [Abstract]. Gastroenterology 2016;150:S182-3.
63. D'Haens GR, Panaccione R, Higgins P, , et al. 856 Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial [Abstract]. Gastroenterology 2016;150:S183.
64. Souto A, Salgado E, Maneiro JR, , et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol (Hoboken, NJ) 2015;67:117-27.
65. Charles-Schoeman C, Fleischmann R, Davignon J, , et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Clin Gastroenterol Hepatol 2015;67: 616-25.
66. EMA-Refusal of the marketing authorisation for Xeljanz (tofacitinib). 2013. http://www.ema.europa. eu/docs/en-GB/document-library/Summary-of-opinion--Initial-authorisation/human/002542/WC500146629.pdf (accessed 15 Jul 2016).
67. Cohen S, Radominski SC, Gomez-Reino JJ, , et al. Analysis of infections and all-cause mortality in phase II, phase III, long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2924-37.
68. Curtis JR, Lee EB, Kaplan IV, , et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 2016;75:831-41.
69. Yamaoka K. Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster. Drug Saf 2016;39:823-40.
70. Vermeire S, Schreiber S, Petryka R, , et al. OP020. Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the Phase 2 FITZROY study [Abstract]. J Crohn's Colitis 2016;10: S15.2-S17.
71. Mohamed M-EF, Camp HS, Jiang P, , et al. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clin Pharmacokinet Published Online First: 6 Jun 2016. doi:10.1007s40262-016-0419-y
72. Beattie D, Tsuruda P, Shen F, , et al. P069. TD-1473, a novel, potent, orally administered, GI-targeted, pan-Janus kinase ( JAK) inhibitor [Abstract]. J Crohn's Colitis 2016;10:S123.
73. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010;6:489-97.
74. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-22.
75. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307.
76. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, , et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009;78:743-68.
77. Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: Its role in pathogenesis and therapy. J Clin Invest 2015;125:1379-87.
78. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8:753-63.
79. Degagné E, Saba JD. S1 pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin Exp Gastroenterol 2014;7:205-14.
80. Sandborn WJ. New targets for small molecules in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2015;11:338-40.
81. Scott FL, Clemons B, Brooks J, , et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol 2016;173:1778-92.
82. Cohen JA, Arnold DL, Comi G, , et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:373-81.
83. Sandborn WJ, Feagan BG, Wolf DC, , et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374:1754-62.
84. Sandborn W, Feagan BG, D'Haens GR, , et al. 857 Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomized, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate to severe ulcerative colitis [Abstract]. Gastroenterology 2016;150:S183.
85. Juif P-E, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol 2016;12:879-95.
86. Kappos L, Radue EW, O'Connor P, , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
87. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366:339-47.
88. FDA. Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. 2013. http://www. fda.gov/Drugs/DrugSafety/ucm456919.htm (accessed 16 Jul 2016).
89. Van Assche G, Van Ranst M, Sciot R, , et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
90. Peters SL, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 2007;7:186-92.
91. Meissner A, Limmroth V. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS). Mult Scler Relat Disord 2016;8:19-26.
92. D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 2016;7:18-33.
93. Jönsson S, Andersson G, Fex T, , et al. Synthesis and Biological Evaluation of New 1, 2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004;47:2075-88.
94. Comi G, Jeffery D, Kappos L, , et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366: 1000-9.
95. D'Haens G, Sandborn WJ, Colombel JF, , et al. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35.
96. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011;306:173-9.
97. Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 2014;262(Pt A):66-71.
98. Wegner C, Stadelmann C, Pförtner R, , et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-43.
99. Yang JS, Xu LY, Xiao BG, , et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3-9.
100. Sun J, Shen X, Dong J, , et al. Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function. Int Immunopharmacol 2015;29:423-32.
101. Monteleone G, Kumberova A, Croft NM, , et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-9.
102. Mantel PY, Schmidt-Weber CB. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol 2011;677:303-38.
103. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-71.
104. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
105. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998;95:737-40.
106. Di Sabatino A, Pickard KM, Rampton D, , et al. Blockade of transforming growth factor beta upregulates T-box transcription factor T-bet, increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut 2008;57:605-12.
107. Monteleone G, Fantini MC, Onali S, , et al. Phase I clinical trial of smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012;20:870-6.
108. Monteleone G, Neurath MF, Ardizzone S, , et al. Mongersen, an oral SMAD7 antisense oligonucleotide, Crohn's disease. N Engl J Med 2015;372:1104-13.
109. Monteleone G, Di Sabatino A, Ardizzone S, , et al. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment Pharmacol Ther 2016;43:717-24.
110. Vermeire S. Oral SMAD7 antisense drug for Crohn's disease. N Engl J Med 2015;372:1166-7.
111. Peyrin-Biroulet L, Reinisch W, Colombel JF, , et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63:88-95.
112. Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn's Disease. 2016. http://ir.celgene.com/releasedetail.cfmreleaseid=988651 (accessed 20 Sep 2016).
113. Fichtner-Feigl S, Strober W, Kawakami K, , et al. IL-13 signaling through the IL-132 receptor is involved in induction of TGF-1 production and fibrosis. Nat Med 2006;12:99-106.
114. Medina C, Santos-Martinez MJ, Santana A, , et al. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol 2011;224:461-72.
115. Fujio K, Komai T, Inoue M, , et al. Revisiting the regulatory roles of the TGF-family of cytokines. Autoimmun Rev 2016;15:917-22.
116. Nielsen OH, Seidelin JB, Ainsworth M, , et al. Will novel oral formulations change the management of inflammatory bowel diseaseExpert Opin Investig Drugs 2016;25:709-18.
117. Danese S, Fiorino G, Peyrin-Biroulet L. Targeting SMAD7 in Crohn's disease by mongersen: therapeutic revolution under wayGastroenterology 2015;149:1121-3.
118. Gentile I, Maraolo AE, Buonomo AR, , et al. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov 2015;10:1363-77.
119. Stremmel W, Merle U, Zahn A, , et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54: 966-71.
120. Harris MS, Hartman D, Lemos BR, , et al. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohn's Colitis 2016;10:631-40.